Shares of PRA Health Sciences Inc (NASDAQ:PRAH) have been given a consensus rating of “Buy” by the twelve research firms that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $115.78.
Several equities research analysts have issued reports on PRAH shares. Wolfe Research upgraded shares of PRA Health Sciences from a “peer perform” rating to an “outperform” rating and set a $123.00 price objective for the company in a research note on Thursday, November 14th. BidaskClub raised PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 21st. Barclays boosted their price objective on PRA Health Sciences from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Goldman Sachs Group started coverage on PRA Health Sciences in a research note on Thursday, September 19th. They set a “buy” rating and a $126.00 price objective for the company. Finally, Zacks Investment Research lowered PRA Health Sciences from a “buy” rating to a “hold” rating and set a $108.00 target price on the stock. in a research report on Tuesday, November 5th.
In other PRA Health Sciences news, major shareholder Fund Holdings L.P. Kkr sold 6,666,684 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $97.41, for a total value of $649,401,688.44. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.95% of the stock is currently owned by corporate insiders.
Shares of PRA Health Sciences stock traded down $0.90 during trading hours on Tuesday, reaching $108.52. The stock had a trading volume of 6,307 shares, compared to its average volume of 394,306. The firm has a market capitalization of $6.88 billion, a price-to-earnings ratio of 27.61, a P/E/G ratio of 1.48 and a beta of 1.13. PRA Health Sciences has a 1 year low of $82.12 and a 1 year high of $121.98. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 1.65. The firm has a 50 day simple moving average of $102.08 and a two-hundred day simple moving average of $98.32.
PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, October 30th. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.29 by $0.03. PRA Health Sciences had a net margin of 8.00% and a return on equity of 27.73%. The firm had revenue of $780.70 million during the quarter, compared to the consensus estimate of $771.64 million. During the same quarter in the prior year, the company earned $1.13 EPS. The company’s revenue was up 8.8% on a year-over-year basis. Sell-side analysts forecast that PRA Health Sciences will post 4.6 EPS for the current year.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Featured Story: Golden Cross
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.